Loading...
Market
What will be Novo Nordisk's Wegovy sales figures for Q4 2024?
3
Resolution / Starting Odds
Below $1 billion • 25%
$1 billion to $1.5 billion • 25%
$1.5 billion to $2 billion • 25%
Above $2 billion • 25%
Novo Nordisk's quarterly financial reports and earnings call transcripts
Story
Novo Nordisk's GLP-1 Wegovy Receives EMA Approval for Heart Failure Label Update on Thursday
Sep 19, 2024, 08:00 PM
Novo Nordisk, the Danish drugmaker, announced that its drug Wegovy has received a positive opinion from the European Medicines Agency for a label update. The update will reflect reduced heart failure symptoms and improved physical function in patients with obesity-related heart failure with preserved ejection fraction (HFpEF). The recommendation, announced on Thursday, is based on results from the STEP HFpEF trials. Wegovy is the first GLP-1 medication to receive such an endorsement for obesity-related heart failure.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
< $500 million • 33%
$500 million - $1 billion • 33%
> $1 billion • 34%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Price reductions • 25%
Price increases • 25%
No change • 25%
Other • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Under 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Over 30% • 25%
